Objective: To investigate the effect and prognostic influencing factors of Arotinib in the treatment of terminal non-small cell lung cancer(NSCLC).Methods: 84 patients with terminal NSCLC who had been treated by the second-line program at least in our hospital from October 2018 to December 2019 were enrolled. They were treated with Arotinib by oral for 3 weeks. Using a life table method to evaluate the overall survival rate of terminal NSCLC patients, and the prognostic influencing factors of terminal NSCLCwere analyzed by Cox proportional hazards regression model. Results: Among 84 terminal NSCLC patients, the objective effective rate was 11.9%, and the disease control rate was 51.2%. The 84 terminal NSCLC patients were followed up until June 30, 2020. The median survival time was 9.19 months. The overall survival rate was 31.0%. KRAS+, ALK+,TP53+ were positively correlated with the death of terminal NSCLC patients(P<0.05), EGFR+were negatively correlated with the death of terminal NSCLC patients(P<0.05).In the analysis of influencing factors, smoking, EGFR-, KRAS+, ALK+ and TP53+ were risk factors of terminal NSCLC patients(P<0.05).Conclusion: Arotinib has a certain effect in the treatment of terminal NSCLC. Terminal NSCLC show a poor prognosis with smoking, EGFR-, KRAS+, ALK+ and TP53+, which can be used to evaluate the prognosis of NSCLC after Arotinib treatment. |
[1] BAO S M,HU Q H,YANG W T,et al.Targeting epidermal growth factor receptor in non-small-cell-lung cancer:current state and future perspective[J].Anticancer Agents Med Chem,2019,19(8):984-991
[2] 陆宽,张博,窦欣,等.MSCT在含铂双药方案全身化疗治疗非小细胞肺癌的疗效评价中的应用价值[J].肿瘤药学,2018,8(6):955-959.
[3] 潘伟佳.肺腺癌化疗与口服表皮生长因子受体酪氨酸激酶抑制剂的疗效[D].郑州:郑州大学,2018.
[4] 邹宜覃,宁方政,张景熙,等.盐酸安罗替尼治疗晚期非小细胞肺癌临床疗效及影响因素分析[J].国际呼吸杂志,2020,40(7):493-498.
[5] 刘贞,王彩莲.非小细胞肺癌靶向治疗回顾与进展[J].现代医学,2018,46(2):229-234.
[6] ZHOU C C,YAO L D.Strategies to improve outcomes of patients with egrf-mutant non-small cell lung cancer:review of the literature[J].J Thorac Oncol,2016,11(2):174-186.
[7] WANG Z J,DUAN J C,WANG G Q,et al.Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for patients with NSCLC treated with PD-(L)1 inhibitors[J].J Thorac Oncol,2020,15(4):556-567.
[8] 李凡敏,魏茂刚,范华,等.培美曲塞联合铂类方案三线治疗晚期非小细胞肺癌的临床疗效及疾病预后[J].实用癌症杂志,2018,33(9):1424-1426.
[9] 王俊.安罗替尼治疗恶性肿瘤的临床研究进展[J].中国肿瘤,2019,28(5):359-366.
[10] 苏雨栋,孟昭婷,徐晓燕,等.安罗替尼治疗KRAS突变型晚期肺腺癌1例[J].中国肺癌杂志,2018,21(5):428-430.
[11] 顾伟国,余锋,聂珊琳,等.Research progress in clinical research of adjuvant targeted therapy with EGFR-TKI for postoperative non-small cell lung cancer[J].临床肿瘤学杂志,2018,23(12):1131-1134.
[12] STEWART E L,TAN S Z,LIU G,et al.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review[J].Transl Lung Cancer Res,2015,4(1):67-81.
[13] 凌云,邱田,李卓,等.非小细胞肺癌中EGFR和KRAS基因突变的特点及与临床病理特征的关系[J].临床与实验病理学杂志,2015,31(5):536-541.
[14] 刘铁军.基于EGFR、KRAS、ALK分型非小细胞肺癌临床病理特点和预后的研究[D].北京:北京协和医学院,2015.
[15] 张其程,徐克.自噬在EGFR-TKI类肿瘤靶向药物对肺癌的治疗和耐药中作用的研究进展[J].中国肺癌杂志,2016,19(9):607-614.
[16] LIU Y,LI S,CHEN D,et al.Clinical diagnosis of EML4-ALK mutation in NSCLC by a gold nanoparticle beacon[J].RSC Adv,2016,6(104):102398-102405.
[17] LABBÉ C,CABANERO M,KORPANTY G J,et al.Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer(NSCLC)[J].Lung Cancer,2017,111:23-29.
[18] WU Y L,CHENG Y,ZHOU X,et al.Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050):a randomised,open-label,phase 3 trial.[J].Lancet Oncol,2017,18(11):1454-1466.
[19] 郑剑滔,郑斌,郭朝晖,等.非小细胞肺癌患者EML4-ALK基因表达与临床特征及近期生存的关系[D].福州:福建医科大学,2014.
[20] 孙海基.TP53、KRAS和EGFR基因在非小细胞肺癌顺铂辅助化疗中肿瘤标记物的研究[D].济南:山东师范大学,2009. |
